AMENDMENT NO. 2 TO THE COLLABORATION AGREEMENT AND RELEASECollaboration Agreement and Release • July 29th, 2020 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This Amendment No. 2 to the Collaboration Agreement and Release (this “Amendment”) is entered into as of the 2nd day of May, 2016 (the “Amendment Effective Date”) by and between Amgen Inc., a Delaware corporation with a place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and AstraZeneca Collaboration Ventures, LLC, a Delaware limited liability company with a place of business at 1800 Concord Pike, Wilmington, Delaware 19850 (“AstraZeneca” or “Partner”). Amgen and AstraZeneca are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. AstraZeneca Pharmaceuticals LP, the parent corporation of Partner (“AZ Parent”), pursuant to Section 15.16 (AstraZeneca Guarantee) of the Agreement (as defined below) is a party to this Amendment as guarantor of Partner’s obligations under the Agreement.
